NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer

Interventions: Drug: fluorouracil
Drug: gefitinib
Drug: irinotecan hydrochloride
Drug: leucovorin calcium

First Posted Date: 2003-06-25

Last Posted Date: 2013-03-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 22

Registration Number: NCT00026364

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Treating Nonalcoholic Steatohepatitis (NASH) With Metformin

Phase 2

Completed

Conditions: Hepatitis

First Posted Date: 2003-06-24

Last Posted Date: 2011-07-20

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 28

Registration Number: NCT00063232

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Adenocarcinoma of the Colon
Adenocarcinoma of the Rectum
Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage IV Colon Cancer
Stage IV Rectal Cancer

Interventions: Drug: iodine I 131 monoclonal antibody CC49-deltaCH2

First Posted Date: 2003-06-20

Last Posted Date: 2013-01-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT00023933

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

Free-Living Physical Activity and Energy Expenditure

Completed

Conditions: Obesity

First Posted Date: 2003-06-19

Last Posted Date: 2010-03-18

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 15

Registration Number: NCT00062998

Locations: 🇺🇸
St. Luke's-Roosevelt Hospital Center, New York, New York, United States

Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor

Phase 2

Completed

Conditions: Neutropenia
Sarcoma

Interventions: Biological: filgrastim
Drug: amifostine trihydrate
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: ifosfamide
Drug: topotecan hydrochloride
Drug: vincristine sulfate
Procedure: conventional surgery
Radiation: low-LET cobalt-60 gamma ray therapy
Radiation: low-LET electron therapy
Radiation: low-LET photon therapy

First Posted Date: 2003-06-18

Last Posted Date: 2013-02-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 130

Registration Number: NCT00002643

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Medical City Dallas Hospital, Dallas, Texas, United States
🇺🇸
Long Beach Memorial Medical Center, Long Beach, California, United States

and more 46 locations

A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma

Phase 2

Completed

Conditions: Melanoma

First Posted Date: 2003-06-18

Last Posted Date: 2012-08-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00062933

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: BMS-214662
Biological: trastuzumab
Other: pharmacological study

First Posted Date: 2003-06-17

Last Posted Date: 2013-01-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 28

Registration Number: NCT00022529

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Treating Nonalcoholic Steatohepatitis With Pioglitazone

Phase 2

Completed

Conditions: Hepatitis

Interventions: Drug: Actos (Pioglitazone)

First Posted Date: 2003-06-13

Last Posted Date: 2012-12-19

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 18

Registration Number: NCT00062764

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Written Self-disclosure for Youth Abdominal Pain

Phase 2

Completed

Conditions: Abdominal Pain

First Posted Date: 2003-06-12

Last Posted Date: 2010-01-13

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 160

Registration Number: NCT00062608

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Melanoma (Skin)

Interventions: Drug: semaxanib
Drug: thalidomide

First Posted Date: 2003-06-12

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT00017316

Locations: 🇺🇸
University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy